MAPK11 and breast carcinoma: LY2228820 is a selective inhibitor of p38α and p38β and was created for use in cancer [91], where it was shown to significantly inhibit tumor proliferation in in vitro and in vivo models of melanoma, non-small-cell lung cancer, ovarian cancer, glioma, myeloma, and breast cancer.